Skip to main
CAPR
CAPR logo

Capricor Therapeutics (CAPR) Stock Forecast & Price Target

Capricor Therapeutics (CAPR) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Capricor Therapeutics Inc has significantly enhanced its valuation of deramiocel for treating Duchenne muscular dystrophy cardiomyopathy, raising it to $2.30 billion from a previous estimate of $794 million, indicating strong market potential for the therapy. The positive results from Phase III clinical trials, particularly the notable improvements in the PUL 2.0 Mid-level Dimension and other clinical metrics, further underscore the efficacy of deramiocel, bolstering investor confidence. Additionally, the company’s continued innovation with its proprietary StealthXTM platform for delivering therapeutics positions it favorably within the biotechnology sector, suggesting strong future financial performance.

Bears say

Capricor Therapeutics Inc. faces a substantial risk associated with the clinical development of its lead product, deramiocel, particularly regarding potential failures in safety, efficacy, and regulatory approval, which could significantly impede progress and market acceptance. The company must also contend with the challenge of declining left ventricular ejection fraction (LVEF) in Duchenne muscular dystrophy patients, which complicates treatment outcomes and may generate volatility in clinical trial interpretations. Furthermore, uncertainties surrounding funding and the potential delays in product launch underscore the fragility of Capricor’s financial outlook, raising concerns about its ability to sustain operations and advance its therapeutic pipeline effectively.

Capricor Therapeutics (CAPR) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Capricor Therapeutics (CAPR) Forecast

Analysts have given Capricor Therapeutics (CAPR) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Capricor Therapeutics (CAPR) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Capricor Therapeutics (CAPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.